Fixing Healthcare Bottlenecks from First Principles: Interview with Enspectra Health CEO Gabriel Sanchez

episode

Scott Nelson Live not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Scott Nelson Live

The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec 57 min · 16 Dec 2025

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD 52 min · 10 Dec 2025

All episodes from Scott Nelson Live →

Report any issue

Source

Recorded17 Dec 2024

Publisherfeeds.transistor.fm ↗

Handlerec:13866230

Show notes

In this episode of Medsider Radio, we sat down with Gabriel Sanchez, co-founder and CEO of Enspectra Health. The company's flagship VIO platform is the first FDA-cleared imaging modality for dermatology in over 25 years. Gabriel holds a B.S. in mechanical engineering from MIT and an M.S. and Ph.D. from Stanford University, where he also served as an instructor in bioengineering and launched Enspectra to commercialize his groundbreaking research. VIO enables high-resolution, noninvasive imaging for skin cancer detection and health biometrics.In this interview, Gabriel talks about his transition from academia to startups, how he narrowed down his idea to meet a pressing need in healthcare, the importance of speaking FDA’s language—or finding someone who does—and how he balances dilutive and non-dilutive funding. Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ lifescience investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Gabriel Sanchez.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.